BNP Paribas Financial Markets
LYEL icon

BNP Paribas Financial Markets’s Lyell Immunopharma LYEL Stock Holding History

BNP Paribas Financial Markets’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.1K Sell
2,097
-1,073
-34% -$25.1K ﹤0.01% 4786
2025
Q4 		$97.6K Buy
3,170
+2,815
+793% +$63K ﹤0.01% 4390
2025
Q3 		$5.76K Buy
355
+2
+0.6% +$23 ﹤0.01% 5084
2025
Q2 		$3.12K Sell
353
-7,960
-96% -$72.5K ﹤0.01% 5010
2025
Q1 		$89.4K Sell
8,313
-4,370
-34% -$53.5K ﹤0.01% 4075
2024
Q4 		$162K Buy
+12,683
New +$251K ﹤0.01% 3974

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets's LYEL Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Lyell Immunopharma (LYEL) stake by 34% in Q1 2026, selling an estimated $25.1K and leaving 2,097 shares worth $42.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4786.

BNP Paribas Financial Markets first reported a position in LYEL in Q4 2024 and has held it in 6 quarters since. The position peaked at $162K in Q4 2024. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • BNP Paribas Financial Markets held 2,097 shares of Lyell Immunopharma worth $42.1K as of Q1 2026.
  • BNP Paribas Financial Markets sold 1,073 Lyell Immunopharma shares in Q1 2026, an estimated $25.1K.
  • Lyell Immunopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4786 holding.
  • BNP Paribas Financial Markets first reported a position in Lyell Immunopharma in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Lyell Immunopharma position peaked at $162K in Q4 2024.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.